PF-07258669

Phase 1Small molecule

Pfizer

PF-07258669 is one of 31 small molecule programs targeting Malnutrition. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

MalnutritionPhase 1

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Malnutrition

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

1 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

9 3

Lialda

Takeda

Approved

—4

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Garamycin

2 7

Penbritin-S

Bristol-Myers Squibb

Phase 3

1 8

Flagyl

DDePuy Orthopaedics

Phase 3

1 9

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Typhoid Conjugate Vaccine

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult2 trials

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06706869·26 enrolled

A Study of PF-07258669 In Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05113940·120 enrolled

Single Ascending Dose1 trial

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT04628793·29 enrolled

Malnutrition1 trial

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

Terminated· Pfizer logo

Pfizer·Phase 1·NCT07086664·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PF-07258669. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-07258669 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-07258669. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-07258669

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult2 trials

Single Ascending Dose1 trial

Malnutrition1 trial

References

Drug Info

Quick Facts

Related News